Anhui Pioneer Pharmaceutical Co. Ltd.

This study aimed to investigate the pharmacokinetic characteristics of levamlodipine besylate tablets (5 mg) developed and produced by Anhui Pioneer Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after a meal; using amlodipine besylate tablets (Norvasc®, 10 mg) produced by Pfizer Pharmaceuticals Co., Ltd. as the reference preparation, the pharmacokinetic parameters Cmax and AUC0-72 of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.

This study aimed to study the pharmacokinetic characteristics of a single fasting oral dose of bismuth potassium citrate tablets [0.3 g (equivalent to 110 mg bismuth)] developed and produced by Anhui Pioneer Pharmaceutical Co., Ltd.; using bismuth potassium citrate tablets [Gastrodenol®, 120 mg (calculated as Bi2O3)] certified by Tora Laboratories S.L. as the reference preparation, and to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations to evaluate the safety of the test preparation.

This study aimed to study the pharmacokinetic characteristics of a single fasting and postprandial oral administration of compound glycyrrhizin tablets [Glycyrrhizic acid monoammonium salt S (calculated as glycyrrhizin) 25 mg/glycine 25 mg/methionine 25 mg] developed and produced by Anhui Pioneer Pharmaceutical Co., Ltd. in healthy subjects; using the certified compound glycyrrhizin tablets [Meineng®, glycyrrhizic acid 25 mg (Glycyrrhizic acid monoammonium salt 35 mg)/glycine 25 mg/DL-methionine 25 mg] of Minophagen Pharmaceutical Co., Ltd. as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, to evaluate the human bioequivalence of the two preparations, and to observe the safety of the two preparations in healthy subjects.